Skip to content

Duration of Perioperative Antibiotics in Pancreatoduodenectomy

Duration of Perioperative Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy: a Randomized Controlled Trial

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07043855
Enrollment
558
Registered
2025-06-29
Start date
2026-05-11
Completion date
2028-12-01
Last updated
2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Complications, Pancreatoduodenectomy, PPPD

Keywords

preoperative antibiotics, perioperative antibiotics, prophylactic antibiotics

Brief summary

The goal of this clinical trial is to compare two perioperative antibiotic prophylaxis regimens in adult patients undergoing pancreatoduodenectomy (PD) or pylorus-preserving pancreatoduodenectomy (PPPD). The main question it aims to answer is: Is a single preoperative dose of cefazolin non-inferior to the conventional extended regimen (preoperative cefoxitin followed by 3 days of postoperative cefotaxime plus metronidazole) in preventing surgical site infection? Researchers will compare the single-dose cefazolin regimen with the conventional extended regimen to determine whether the shorter regimen results in a comparable rate of postoperative surgical site infection. Participants will be randomized 1:1 to one of the two regimens and followed for 30 days after surgery for surgical site infection and other infectious complications.

Detailed description

1. Brief background Pancreatoduodenectomy (PD) is one of the major hepatobiliopancreatic surgical procedures, with postoperative infectious complication rates reaching approximately 20-40%. International guidelines recommend a single preoperative dose of cefazolin as antibiotic prophylaxis for PD. However, due to concerns about high infectious complication rates, some institutions administer antibiotics for more than 24 hours postoperatively. This study compares surgical site infection rates between the internationally recommended single-dose cefazolin regimen and the current practice at Asan Medical Center, which consists of a preoperative second-generation cephalosporin (cefoxitin) followed by postoperative cefotaxime plus metronidazole for 3 days. Through this comparison, the study seeks to contribute to establishing effective and safe antibiotic prophylaxis guidelines and to advancing antimicrobial stewardship efforts for this patient population. 2. Protocol summary This phase III, single-center, randomized, non-inferiority trial conducted at Asan Medical Center, Seoul, compares two antibiotic prophylaxis regimens in adult patients undergoing PD or PPPD. A total of 558 participants will be enrolled over a two-year period from IRB approval, with follow-up through 30 days postoperatively. After informed consent and stratification by preoperative biliary stent status, participants will be randomized 1:1 to: Single-dose arm: a single dose of cefazolin administered within 1 hour before skin incision. Conventional (extended) arm: a single dose of cefoxitin within 1 hour before skin incision, followed by cefotaxime plus metronidazole on postoperative days 0-3. The primary outcome is the incidence of surgical site infection within 30 days after surgery. 3. Statistical considerations The trial is designed to assess the non-inferiority of the single-dose cefazolin regimen relative to the conventional extended regimen. Assuming a 30-day surgical site infection rate of 20% in the control group, a non-inferiority margin of 10%, a one-sided alpha of 0.025, and 80% power, 252 participants per group (504 total) are required. Accounting for an anticipated 10% dropout rate, a total of 558 participants will be enrolled. The non-inferiority test for the difference between two independent proportions was used for sample size calculation (PASS software, version 15). 4. Analysis population The primary analysis will be performed on a modified intention-to-treat (mITT) basis, including all randomized participants who underwent pancreatic resection, regardless of the final resection type (e.g., conversion from planned pancreatoduodenectomy to total pancreatectomy). Participants who underwent surgical exploration without resection (open-and-close) are excluded, as they are not at risk for the primary endpoint. Participants are analyzed according to their randomized treatment assignment regardless of dosing protocol adherence. Sensitivity analyses, including a conservative intention-to-treat analysis and a per-protocol analysis, will also be performed.

Interventions

DRUGsingle dose preoperative antibiotic

Arm A is a single preoperative dose of cefazolin administered within 1 hour before surgery

DRUGProlonged perioperative antibiotics

Preoperative Single-Dose Cefoxitin followed by Three-Day Cefotaxime and Metronidazole Prophylaxis

Sponsors

Asan Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male and female adults aged 18 to 80 years old scheduled for pancreaticoduodenectomy for any indication (including open, laparoscopic, and robotic surgery). * Patients who have received sufficient explanation about this clinical trial and have voluntarily decided to participate and provided written informed consent.

Exclusion criteria

* History of Type 1 immediate hypersensitivity reaction to cefazolin, cefotaxime, or metronidazole. * Active or uncontrolled infection prior to surgery for which treatment has not been completed. * Use of antibiotics for any reason within 1 week prior to surgery. * Long-term use of immunosuppressants due to other concomitant diseases. * Undergoing dialysis or having renal dysfunction of KDIGO Grade 3 or higher (GFR \< 45). * Pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Surgical site infectionwithin 30 days after PD/PPPDsuperficial/deep/organ-space infection

Countries

South Korea

Contacts

PRINCIPAL_INVESTIGATORSung-Han Kim, MD, PhD

Asan Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026